Tony Coles, MD, a leader in the biotechnology industry, will deliver the commencement address at the summer graduation ceremony of the Johns Hopkins Carey Business School. The ceremony will be held on Tuesday, August 9, 2016, at the Joseph Meyerhoff Symphony Hall in Baltimore, Maryland.
Dr. Coles is a founding investor and chairman and chief executive officer of Yumanity Therapeutics, a company focused on transforming drug discovery for neurodegenerative diseases caused by protein misfolding such as Alzheimer’s, Parkinson’s and amyotrophic lateral sclerosis (ALS). He also serves as chairman and chief executive officer for the privately held company TRATE Enterprises.
Dr. Coles (at left) currently serves on the board of CRISPR Therapeutics, a biopharmaceutical company focused on developing transformative gene-based medicines for patients with serious diseases. He is vice chair of the board of trustees for Johns Hopkins University and a member of the board of trustees for Johns Hopkins Medicine. He is also a member of the board of directors of McKesson Corporation, a leader in the health care services industry.
“Tony Coles is a business leader who is working to find solutions to some of our greatest health care challenges,” said Bernie Ferrari, dean of the Carey Business School. “He exemplifies what it means to practice business with humanity in mind and we are very pleased to have him as our commencement speaker.”
Dr. Coles received his undergraduate degree at Johns Hopkins University before earning his medical degree from Duke University. He also has a master’s degree in public health from Harvard University.
Previously, Dr. Coles was chairman and chief executive officer of Onyx Pharmaceuticals, based in South San Francisco, CA. During his tenure, Onyx introduced two innovative cancer medicines and established the company's international presence. Prior to joining Onyx, Dr. Coles was president, chief executive officer and a member of the board of directors of NPS Pharmaceuticals. He previously held executive positions at Vertex Pharmaceuticals, Bristol-Myers Squibb and Merck.
Dr. Coles was named to the National Institutes of Health working group tasked with charting the course for President Obama’s Precision Medicine Initiative, now part of the PMI Cohort Program Advisory Panel. He also serves as a member of the council for the Smithsonian Institution’s National Museum of African American History and Culture in Washington, DC; a member of the board of trustees for The Metropolitan Museum of Art in New York City; and a member of the Council on Foreign Relations, an independent, nonpartisan membership organization, think tank and publisher.
David M. Rubenstein, the co-founder and co-chief executive officer of The Carlyle Group, will deliver a graduation address at the Carey Business School’s spring commencement on May 17, 2016.
Founded in 2007, the Johns Hopkins Carey Business School supports business knowledge development and education through its own initiatives, innovations and collaborative programs across the Johns Hopkins University. The Carey Business School creates and shares knowledge that shapes business practices while educating business leaders who will grow economies and societies and are exemplary citizens.